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Spinal cord ischemia remains a devastating com-
plication of thoracoabdominal aortic surgery, with
paraparesis or paraplegia occurring in as many as
21% of procedures.1,2
The pathophysiologic mechanisms that underlie
hypoxic/ischemic injury to the spinal cord have not
been totally elucidated, but recent studies suggested
that the release of excitatory amino acids into the
extracellular space of the central nervous system by
ischemic cells may play a key role in the neuronal cell
death occurring in the ischemic spinal cord.3,4
Glutamate and aspartate may destroy neuronal cells
through their actions on N-methyl-D-aspartate
(NMDA) and non-NMDA receptors by inducing
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Purpose: Excitotoxic mechanisms have been implicated in the pathophysiology of spinal
cord ischemic injury induced by aortic cross-clamping. We investigated the effects of the
anti-excitotoxic drugs magnesium sulfate (MgSO4) and riluzole in a rabbit model of
spinal cord ischemia.
Method: The infrarenal aorta of New Zealand albino white rabbits (n = 68) was occlud-
ed for 40 minutes. Experimental groups included: a control group, which received only
vehicle (n = 17); group A (n = 17), which received riluzole (8 mg/kg) before clamping;
group B (n = 17), which received MgSO4 (100 mg/kg) before clamping; and group C
(n = 17), which received riluzole (8 mg/kg) and MgSO4 (100 mg/kg) before clamping.
Five additional rabbits had the same operation, but did not undergo aortic clamping
(sham operation). The neurological status of the rabbits was assessed at 24 hours, 48
hours, and then daily for as long as 120 hours by using a modified Tarlov scale. The rab-
bits were killed at 24 hours (n = 3 per group), 48 hours (n = 4 per group), and 120
hours (n = 10 per group) postoperatively. Spinal cords were harvested for histopatho-
logic and immunohistochemistry examinations for microtubule-associated protein-2
(MAP-2), a cytoskeletal protein specific from neurons.
Results: No major adverse effect was observed with either riluzole or MgSO4. All con-
trol rabbits became severely paraplegic. All riluzole-treated and MgSO4-treated animals
had a better neurological status than control animals. Typical morphological changes
characteristic of neuronal necrosis in the gray matter of control animals was demon-
strated by means of the histopathological examination, whereas riluzole or magnesium
prevented or attenuated necrotic phenomenons. Moreover, MAP-2 immunoreactivity
was completely lost in control rabbits, whereas it was preserved, either completely or
partially, in rabbits treated with riluzole or magnesium. Riluzole was more effective than
MgSO4 in preventing paraplegia caused by motor neuron injury (P < .01 ). Riluzole and
MgSO4 had no additive neuroprotective effect.
Conclusion: These results demonstrate that riluzole and, to a lesser extent, MgSO4 may
afford significant spinal cord protection in a setting of severe ischemia and may, there-
fore, be considered for clinical use during “high-risk” operations on the thoracic and
thoracoabdominal aorta. (J Vasc Surg 2000;32:179-89.)
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massive sodium and calcium ion influxes into the
cell, resulting in neuronal death.4
NMDA and non-NMDA receptor antagonists
have demonstrated neuroprotective properties both
in vitro and in vivo,3-6 but their major adverse effects
limit their clinical use.7,8
Riluzole (2-amino-6-trifluoromethoxybenzo-
thiazole) is a neuroprotective drug that blocks glu-
tamatergic neurotransmission in the central nervous
system and has demonstrated anti-ischemic proper-
ties both in vitro and in vivo.9 A recent experimen-
tal study also demonstrated that riluzole may pre-
vent spinal cord ischemic injury induced by aortic
cross-clamping.10 Riluzole is currently in clinical use
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Fig 1. Histopathological examination (original magnification, 400×). Representative photomicro-
graphs of lumbar spinal cord sections stained with Klüver-Barrera stain from sham-operated (A), con-
trol (B), riluzole-treated (C), magnesium-treated (D), and riluzole plus magnesium-treated (E) rab-
bits that underwent 40 minutes of spinal cord ischemia and 120 hours of reperfusion. The chosen sec-
tions for illustration of riluzole-treated and riluzole plus magnesium-treated groups (groups A and C)
correspond to rabbits with a Tarlov score of 5. The chosen section for illustration of the magnesium-
treated group (group B) corresponds to a rabbit with a Tarlov score of 2. A, Normal appearance of
motor neurons in the ventral horn of a sham-operated rabbit. B, Necrotic motor neurons in the ven-
tral horn of a control rabbit. C and E, Ventral horn motor neurons of riluzole-treated and riluzole plus
magnesium-treated rabbits appear grossly normal. D, Most motor neurons from a magnesium-treated
rabbit exhibit necrotic changes.
among patients with amyotrophic lateral sclero-
sis,9,11 and it seems devoid of major adverse effects,
suggesting that it may be of use in clinical situations
involving spinal cord ischemia. Magnesium sulfate
(MgSO4) is a well-known NMDA receptor antago-
nist, which is widely used in patients with
preeclampsia and which is presently being evaluated
in the treatment of acute stroke,12,13 suggesting a
potential role in the prevention of spinal cord
ischemic injury.
The aim of this study was to determine whether
MgSO4 administered before aortic clamping was
really capable of preserving the structural integrity of
the spinal cord in a setting of severe ischemia, to
observe whether riluzole was superior to MgSO4 in
preventing spinal cord ischemic injury, and to
demonstrate an eventual additive neuroprotective
effect for riluzole and MgSO4.
MATERIAL AND METHODS
Animal care
Female New Zealand albino white rabbits weigh-
ing 3.5 to 4.5 kg were used in this study. This work
was approved by the local Institutional Animal Care
Committee. All animals received humane care, in
compliance with the “Principles of Laboratory
Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care
and Use of Laboratory Animals” prepared by the
Institute of Laboratory Animal Resources and pub-
lished by the National Institute of Health (NIH
Publication No. 86-23, revised 1985).
Anesthesia and monitoring
Animals fasted for 12 hours and were anes-
thetized with intramuscular ketamine (50 mg/kg)
and xylazine (10 mg/kg). Animals were allowed to
breath spontaneously, and general anesthesia was
maintained with a mixture of 1.5% halothane and
oxygen administered by means of a face cone at a
rate of 6 L/min. The core temperature was contin-
uously monitored with a rectal probe inserted 5 cm
into the rectum. Rectal temperature was registered
from the onset of anesthesia to 1 hour of reperfusion
and supported by a heating lamp throughout the
procedure. A catheter (24 gauge) was placed in a
marginal ear vein, and preoperative Cefazolin (10
mg/kg) was given as a single dose. The heartbeat
was monitored throughout the procedure (monitor
model 78353B, Hewlett-Packard, Palo Alto, Calif).
Catheters (24 gauge) were sterilely placed in the
central ear artery and right femoral artery to moni-
tor proximal and distal arterial blood pressure,
respectively. Percutaneous arterial oxygen saturation
(SaO2) was continuously monitored.
Operative technique
Animals were placed in the right lateral decubi-
tus position. After sterile preparation, a 10-cm flank
incision was made, and the infrarenal aorta was
exposed through a retroperitoneal approach. The
aorta was isolated from the renal arteries down to
the aortic bifurcation. Each animal was given 150
U/kg heparin intravenously 10 minutes before the
aorta was occluded. The effects of heparin were not
reversed at the end of the procedure. Aortic occlu-
sion was obtained by placing temporary vascular
clamps (Biover disposable vessel clip, Arex, France)
just below the renal arteries and just above the aor-
tic bifurcation. All animals were subjected to 40
minutes of cross-clamp time. Aortic clamps were
removed after 40 minutes, and satisfactory pulsatile
distal aortic pressure was verified. The flank was
closed in layers. The catheters were removed, and
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Table I. Physiologic parameters
Groups Control (n = 17) Group A (n = 17) Group B (n = 17) Group C (n = 17)
Weight (kg) 3.95 ± 0.9 3.91 ± 0.9 3.98 ± 0.9 4.05 ± 0.8
Rectal temperature (°C)
Maxima 39.2 ± 0.4 39.2 ± 0.3 39.3 ± 0.4 39.3 ± 0.3
Minima 38.4 ± 0.5 38.2 ± 0.4 38.2 ± 0.3 38.2 ± 0.4
PABP (mm Hg)
Preischemia 90 ± 6 92 ± 8 80 ± 5 81 ± 3
Ischemia 10 minutes 92 ± 7 92 ± 4 83 ± 3 88 ± 5
Reperfusion 10 minutes 79 ± 3 82 ± 3 77 ± 2 78 ± 3
DABP (mm Hg) 11 ± 1 11 ± 1 12 ± 2 13 ± 1
The values are expressed as mean ± SD. 
PABP, Proximal arterial blood pressure (central ear artery); DABP, distal arterial blood pressure (femoral artery); Rectal temperature,
maxima and minima recorded from the onset of anesthesia to 1 hour reperfusion. 
There were no significant differences in physiological parameters among the four groups.
the femoral artery was repaired with 8-0 polypropy-
lene suture. Sham-operated animals underwent the
same operative conditions, but without aortic
clamping. Animals were allowed to recover in their
cages, with free access to food and water after 6
hours postoperatively.
Postoperative period and sacrifice.
Credé’s maneuver was used twice daily to empty
the bladders of the paraplegic animals. Animals were
randomly assigned to be humanely killed at 24 hours
(n = 3 per group), 48 hours (n = 4 per group), or
120 hours (n = 10 per group) postoperatively. Sham-
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Fig 2. Microtubule-associated protein-2 immunohistochemistry examination (original magnification,
400×). Microtubule-associated protein-2 immunoreactivity in lumbar spinal cord sections from sham-
operated (A), control (B), riluzole-treated (C), magnesium-treated (D), and riluzole plus magnesium-
treated (E) rabbits that underwent 40 minutes of spinal cord ischemia and 48 hours of reperfusion.
The chosen sections for the illustration of the riluzole-treated and riluzole plus magnesium-treated
groups correspond to rabbits with a Tarlov score of 5. The chosen section for illustration of the mag-
nesium-treated group corresponds to a rabbit with a Tarlov score of 2. A, C, and E, Intense
immunoreactivity was observed in the dendrites and neuronal perikaryon of sham-operated and rilu-
zole-treated or riluzole plus magnesium-treated rabbits. B, The spinal cord of a control rabbit exhibits
a complete loss of microtubule-associated protein-2 immunoreactivity in ventral and dorsal horns. D,
Magnesium treatment did not prevent the loss of microtubule-associated protein-2 immunoreactivity
in the ventral horns of this rabbit.
operated animals were killed at 24 hours postopera-
tively. All animals were killed by a lethal injection of
pentobarbital (200 mg/kg). Spinal cords were quick-
ly harvested for histopathologic and immunohisto-
chemistry examinations. The L3-L4 segment was
fixed in Holland Bouin, and the L5-L6 segment was
frozen in isopentane on dry ice and stored at –70°C.
Study groups
Each study group represents the animals that
survived the entire observation period.
• Sham-operation group (n = 5). The operation was 
performed with the same conditions, but without 
aortic clamping.
• Control group (n = 17). The animals received 
only vehicle (0.9% saline).
• Group A (n = 17). Riluzole (8 mg/kg) was inject-
ed intravenously 30 minutes before aortic clamp-
ing.
• Group B (n = 17). MgSO4 (100 mg/kg) was 
injected intravenously in 10 minutes, 30 minutes 
before aortic clamping.
• Group C (n = 17). Riluzole (8 mg/kg) and 
MgSO4 (100 mg/kg) were injected intravenously 
in 10 minutes, 30 minutes before aortic clamping.
All animals received a similar volume of solu-
tions: 20 mL for the whole procedure.
Riluzole (Research Biochemicals International,
Natick, Mass) was first dissolved in hydrochloric acid
0.1 N, then diluted in distilled water. MgSO4 was
diluted 50% in 0.9%-saline before intravenous injec-
tion in 10 minutes.
Blood magnesium level measurement
Blood samples (0.5 mL) were drawn 10 minutes
before clamping and 10 minutes after the onset of
reperfusion in the control group and in group B.
Assays of serum-ionized magnesium were performed
by means of an automatic clinical analyzer.
Neurologic evaluation
A neurologic assessment was performed in all
animals after 3 hours, 6 hours, 24 hours, and then
daily, in a blinded fashion. Spinal cord function was
graded according to a modified Tarlov scale14: 0, no
movement; 1, slight movement; 2, sits with assis-
tance; 3, sits alone; 4, weak hop; 5, normal hop.
Tissue preparation
Paraffin sections. Spinal cords (L3-L4 seg-
ments) were removed from Holland Bouin after 24-
hour fixation. Specimens were dehydrated in 95%
alcohol for 30 minutes, followed by four changes of
100% alcohol for 1 hour each and five changes of
toluene for 1 hour each under a vacuum at 37°C.
Spinal cords were infiltrated with paraffin and
embedded in paraffin at 57°C under vacuum and
pressure. Sections were cut on a microtome (Leica)
at 7 µm.
Cryostat sections. Spinal cords (L5-L6 seg-
ments) were extracted and fresh frozen in isopentane
at –45°C. Cryostat coronal sections (10 µm) were
mounted on poly-L-lysine-coated slides and tissue
postfixed by successive immersion in 0. 01 mol/L
phosphate buffer (PBS) and 4% paraformaldehyde
for 30 minutes. Sections were then dehydrated in
ethanol baths (50%, 70%, and 100%), air dried, and
stored at –70°C until use.
All animals had their spinal cord studied. For each
spinal cord studied, six sections were placed on
3-aminopropylethoxysilane-coated slides, and 10
slides per rabbit were used for spinal cord analysis.
The neuropathologist, who was blinded to the exper-
imental conditions and treatment, performed the
histopathologic examination with light microscopy.
We used these classifications for spinal cord
analysis: normal, normal appearance of motor neu-
rons in gray matter; grade I, less than 33% of motor
neurons damaged in gray matter; grade II, 33% to
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Table II. Neurologic outcome: Tarlov scores at 24 hours
Tarlov score Sham group (n = 5) Control group (n = 17) Group A (n = 17) Group B (n = 17) Group C (n = 17)
0 17
1 6
2 4 4 1
3 3 5 4
4 1 2
5 5 9 2 10
Differences between groups were analyzed with Kruskal-Wallis tests, followed by Mann-Whitney U tests when significant. Group A vs
control group, P < .01; group B vs control group, P < .01; group C vs control group, P < .01; group A vs group B, P < .01; group A
vs group C, not significant; group B vs group C, P < .01.
66% of motor neurons damaged in gray matter;
grade III, more than 66% of motor neurons dam-
aged in gray matter.
Histopathologic examination
Luxol fast blue staining method. Transverse
sections were deparaffinized by washing twice in
xylene for 5 minutes each and heating at 56°C
overnight, and then they were rehydrated through a
graded series of alcohols and distilled water. Sections
were soaked in 70% alcohol for 10 minutes. They
were stained at 57°C for 16 hours in solution A,
which contained 1 mg Luxol fast blue (Solvent Blue
38, Sigma) and 5 mL 10% acetic acid in 1000 mL of
95% alcohol. The sections were then rinsed in 95%
alcohol and distilled water. They were differentiated
by dipping the sections singly into 0.05% aqueous
Li2CO3 solution for a few seconds and then washing
them through several changes of 70% alcohol and
placing them in distilled water. Sections were then
counterstained with neutral red (Sigma). Sections
were treated with 0.2% NaHSO3 for 1 minute and
then immersed in 0.1 mol/L acetate buffer for 1
minute. Neutral red staining was performed in solu-
tion B, containing 3 vol of 0.05% neutral red stock
solution and 2 vol of 0.1 mol/L acetate buffer for
15 minutes at room temperature. Sections were
rinsed in distilled water, immersed in copper-sulfate-
chrome alum solution for 1 second, and rinsed in




Frozen sections (25 µm) were immersed in 0.3%
H2O2 for 10 minutes, blocked with 5% goat serum
(Vector Laboratories) and 3% Triton for 1 hour at
room temperature, followed by a rinse in PBS. Then
sections were incubated with the primary antibody
overnight. The antiserum used for the study of
cytoskeletal protein expression was a monoclonal
mouse anti-MAP-2 (Clone HM-2, Sigma, diluted
1:500). After the primary incubation and three rins-
es in PBS, sections were incubated in biotinylated
horse anti-mouse IgG (diluted 1:100; Vector
Laboratories) for 3 hours. MAP-2 expression was
visualized with 3’-diaminobenzidine and nickel
chloride (DAB-Ni) staining by using the Vectastain
ABC kit (Vector Laboratories). All sections were
washed a final time in PBS and distilled water and
then mounted with glycerol.
Statistical analysis
Statistical analyses of measured physiologic data
were performed by means of analysis of variance
(ANOVA). All physiologic data are expressed as the
mean plus or minus SD. Tarlov scores were analyzed
with Kruskal-Wallis tests, followed by Mann-
Whitney U tests when significant. Serum magne-
sium levels were compared by means of one-way
ANOVA and Student t tests. Differences were con-
sidered statistically significant when the P value was
less than .05.
RESULTS
Physiologic parameters. No significant differ-
ences existed in the physiological parameters among
the experimental groups (Table I). SaO2 remained in
a normal range in all animals throughout the proce-
dure.
Neurologic outcome. All animals survived the
entire randomly assigned observation period. All
sham-operated animals had a normal postoperative
neurologic function, whereas all control rabbits had a
Tarlov score of 0 at 24 hours and remained severely
paraplegic throughout the observation period.
Neurological outcome was significantly better in rilu-
zole-treated animals from groups A and C (P < .01 for
group A vs control group; P < .01 for group C vs con-
trol group; Tables II, III, and IV). Most animals in
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Table III. Neurologic outcome: Tarlov scores at 48 hours.




3 3 3 2
4 1 2
5 7 2 10
Differences between groups were analyzed with Kruskal-Wallis tests, followed by Mann-Whitney U tests when significant. Group A vs
control group, P < .01; group B vs control group, P < .01; group C vs control group, P < .01; group A vs group B, P < .01; group A
vs group C, not significant; group B vs group C, P < .01.
those groups had either a normal function or a mild-
to-moderate deficit. The addition of MgSO4 to rilu-
zole did not further improve neurological status (P =
not significant for group A vs group C). No riluzole-
treated rabbit had deterioration of neurologic status
between 24 and 120 hours, whereas two rabbits in
group B had a worsening of their neurologic score
between 24 and 48 hours. Neurological outcome was
also significantly better for magnesium-treated animals
(P < .01 for group B vs control group), but most ani-
mals in group B had a moderate-to-severe deficit and
a generally worse neurological status than riluzole-
treated animals (P < .01 for group A vs group B and P
< .01 for group C vs group B, at any time considered).
Blood magnesium levels. Blood magnesium
levels before clamping were 1.68 ± 0.26 mEq/L in
the control group and 6.47 ± 1.3 mEq/L in group
B (range, 4.70 to 8.90 mEq/L; P < .01 for group B
vs control group). During reperfusion, the values
were 1.81 ± 0.15 mEq/L and 3.89 ± 0.48 mEq/L
in the control group and group B, respectively (P <
.01 for group B vs control group). We did not
observe any difference in neurologic outcome
between rabbits with a peak serum magnesium level
higher than 7 mEq/L and those with a peak serum
magnesium level lower than 7 mEq/L.
Histopathologic examination. Luxol fast blue
staining was used as a means of analyzing neuronal
cell death. The extent of ischemic damage was gross-
ly proportional to the Tarlov score. Ischemic dam-
age was observed almost exclusively in gray matter,
which contained typically necrotic neurons in ventral
and dorsal horns and in the intermediate zone.
Sham-operated animals had normal spinal cords.
Rabbits with a Tarlov score of 5 had virtually no
damage, with intact motor neurons in ventral horns.
Rabbits with a Tarlov score of 4 had mild ischemic
injury in the gray matter, with most motor neurons
preserved. Rabbits with a Tarlov score of 3 had
moderate ischemic damage, with confluent focal
necrosis areas involving preferentially central and
medial portions of the anterior gray matter (grade II
lesions). Rabbits with a Tarlov score of 2 or 1 usual-
ly had more extensive necrotic damage in all ventral
gray matter areas (grade III lesions), which also
extended to the dorsal horns. Most riluzole-treated
animals (groups A and C) had either no or few signs
of neuronal damage: 65% of rabbits had normal
spinal cords and only 15% of rabbits had grade III
lesions (Table V). Magnesium-treated animals
(group B) usually had moderate-to-severe gray mat-
ter involvement, with less than 20% of rabbits having
normal spinal cords and 59% of rabbits having grade
III lesions. All control animals had a very severe
involvement, with global necrosis of gray matter:
100% of rabbits had severe grade III lesions. In most
severe cases, white matter surrounding the gray mat-
ter was also involved.
Cytoskeletal proteolysis/microtubule-associ-
ated protein-2 immunohistochemistry. The
cytoskeletal MAP-2 is involved in maintaining neu-
ronal structural integrity. It is extremely sensitive to
ischemia, and MAP-2 immunostaining has been
demonstrated to be a sensitive, accurate, and early
marker of ischemic injury after cerebral ischemia.15
MAP-2 immunoreactivity was expressed exclusively
in the gray matter and grossly paralleled histopatho-
logic findings in most animals. MAP-2 was strongly
expressed in neuronal perikaryon and dendrites of
sham-operated animals and in animals with a Tarlov
score of 5. All control animals had a complete loss of
MAP-2 immunoreactivity, as early as 24 hours after
ischemia. Most riluzole-treated animals (groups A
and C) had either a grossly normal MAP-2
immunoreactivity or focal decrease of immunoreac-
tivity in central gray matter and ventral horns. In
most riluzole-treated animals, MAP-2 immunoreac-
tivity was completely preserved for as long as 5 days
of reperfusion, attesting to the optimal protection
against ischemic cytoskeletal breakdown. Most mag-
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Table IV. Neurologic outcome: Tarlov scores at 120 hours




3 2 3 1
4 1 2
5 6 1 7
Differences between groups were analyzed with Kruskal-Wallis tests, followed by Mann-Whitney U tests when significant. Group A vs
control group, P < .01; group B vs control group, P < .01; group C vs control group, P < .01; group A vs group B, P < .01; group A
vs group C, not significant; group B vs group C, P < .01.
nesium-treated rabbits (group B) had lost more than
66% of MAP-2 immunostaining in ventral horns and
central gray matter, attesting to the incomplete pro-
tection against ischemic cytoskeletal breakdown.
DISCUSSION
Paraplegia remains a serious complication of tho-
racic or thoracoabdominal aortic surgery. Post-
operative neurologic deficits occur in 3.7% to 21% of
patients, depending on the presence of acute dissec-
tion, the level of aortic repair or replacement, the
extension of aortic replacement, the presence of crit-
ical intercostal arteries within the replaced aortic
segment, and the duration of aortic clamping.1,2
Because periods of spinal cord ischemia are often
ineluctable in major cases, pharmacologic interven-
tions have been attempted by some investigators.16
Unfortunately, no drug consistently proved effective
in clinical practice.
Recent experimental and clinical studies con-
firmed the role played by excitotoxic mechanisms in
the pathophysiology of spinal cord ischemic injury
after the repair of thoracoabdominal aortic
aneurysms.3,17 Since the experimental work of Choi
and colleagues,18 evidence has accumulated that the
excitatory amino acids (EAAs), particularly gluta-
mate, the primary neurotransmitter in the spinal
cord, have potent neurotoxic activity during condi-
tions of depleted cellular energy such as ischemia,
when the synaptic reuptake of EAAs, a highly ener-
gy-dependent process, becomes compromised.4
Excitotoxicity is a delayed phenomenon, extending
for several hours after the initiation of ischemia.4
Thus, pharmacological interventions aimed at mini-
mizing spinal cord ischemic injury may be started
before, during, and also after aortic cross-clamping.
NMDA and non-NMDA receptor antagonists
reliably afford protection against ischemic injury in
the brain. These compounds have been shown to be
neuroprotective in several animal models of cerebral
or spinal cord ischemia.3-6 However, these com-
pounds can cause widespread central nervous system
depression, learning impairment, and pathological
changes in defined populations of neurons.7,19 In
addition, recent studies suggested that glutamate
excitotoxicity in the spinal cord is mediated by
NMDA, but also non-NMDA receptors, accounting
for incomplete neuroprotection by NMDA or non-
NMDA receptor antagonists alone.3,6,20
In our study, intravenous MgSO4 resulted in sig-
nificant spinal cord protection. These results are in
accordance with earlier studies on the same
model.21,22 The neuroprotective effects of magne-
sium ions have been used for many years, so MgSO4
has become the standard therapy for preeclampsia in
the United States.12 The dose of magnesium used in
this study (100 mg/kg) corresponds to the loading
dose used in patients with preeclampsia, and blood
magnesium levels in our study correspond to those
reported in humans after an identical loading
dose.12 We did not observe adverse effects, such as
respiratory depression, severe hypotension, or major
electrocardiographic changes, with MgSO4 concen-
trations as high as 8.90 mEq/L. Magnesium ions
cross the intact blood-brain barrier, so intravenous
MgSO4 significantly raises cerebrospinal fluid (CSF)
magnesium concentration.12 It is probable that
higher CSF concentrations may be achieved when
blood-brain barrier integrity is compromised by
ischemia.13 In our study, MgSO4 (100 mg/kg)
given as a single injection before aortic clamping
afforded significant neuroprotection. However,
intravenous MgSO4 afforded incomplete protection,
because most animals had only a partial recovery.
Histopathological and MAP-2 immunohistochem-
istry examinations confirmed that MgSO4 incom-
pletely prevented neuronal necrosis and cytoskeletal
proteolysis. Recently, Simpson et al23 reported that
intrathecal MgSO4 (3 mg/kg) could dramatically
improve neurological status after 45 minutes of tho-
racic aortic clamping in dogs. Differences in peak
CSF magnesium concentration, between our ani-
mals and those reported by Simpson et al,27 may
account for the difference in the animals’ neurologi-
cal outcome between the two studies. Thus, increas-
ing the loading dose of MgSO4 may be required to
achieve superior CSF peak concentrations and subse-
quent neuroprotection. Further studies are warranted
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Table V. Spinal cord histopathologic examination results
Histopathology Sham group (n = 5) Control group (n = 17) Group A (n = 17) Group B (n = 17) Group C (n = 10)
Normal 5 9 3 10
Grade I 1 2
Grade II 3 4 4
Grade III 17 4 10 1
to observe whether a superior loading dose (ie, 150
mg/kg) may provide superior neuroprotection, with-
out adverse effects. Magnesium’s mechanism of neu-
roprotection is probably not univocal. First, magne-
sium is a well-known noncompetitive NMDA recep-
tors blocker and endogenous Ca2+ channel blocker.4
Second, magnesium may cause vasodilation of vessels
supplying the spinal cord by stimulating endothelial
prostacyclin release.24 Third, magnesium may prevent
thrombosis of critical segmental vessels by inhibiting
platelet reactivity.25 Fourth, magnesium may decrease
endothelial and neuronal reperfusion injuries by
directly inhibiting lipid peroxydation and by prevent-
ing glutathione depletion.26,27 Fifth, magnesium may
regulate adenosine triphosphate concentrations and
regenerate adenosine triphosphate after ischemia and
reperfusion.13,28 Magnesium is easily and widely
available, inexpensive, and has been used for years in
clinical practice for the treatment of myocardial
infarction, arrhythmia, and stroke, without adverse
effects.13,29
Riluzole (2-amino-6-trifluoromethoxybenzo-
thiazole) is a neuroprotective drug that blocks 
glutamatergic neurotransmission in the central ner-
vous system. The exact molecular target of riluzole is
not known. However, experimental studies suggest-
ed that riluzole has a complex mechanism of action,
including a direct, but noncompetitive, blockade of
ionotropic EAAs receptors, inhibition of presynaptic
glutamate release, inactivation of voltage-dependent
calcium and sodium channels, and stimulation of a
G-protein-dependent signal transduction path-
way.9,30 Recently, riluzole was demonstrated to acti-
vate a new class of background 2 P domain K+ chan-
nels that are highly expressed in the spinal cord, and
that may play a role during neuronal ischemia.31 It is
not known whether these mechanisms are really
independent of one another. However, it is likely
that the principal effects act synergistically at gluta-
matergic synapses to diminish neurotransmission. In
vivo, riluzole has demonstrated neuroprotective
action in several models of neuronal injury known to
involve excitotoxic mechanisms, including focal or
global cerebral ischemia models, posttraumatic
spinal cord injury models, and spinal cord ischemia
models.9-10 In addition, riluzole has other potential-
ly beneficial effects on the central nervous system,
such as sedative and anesthetic properties, and a
potent anticonvulsant activity.9 Although high doses
of riluzole slightly modify the cardiac action poten-
tial in vitro, this drug does not have appreciable car-
diovascular effects in vivo, particularly on arterial
blood pressure, heart rate, or electrocardiographic
parameters.11 Riluzole is currently given to patients
with amyotrophic lateral sclerosis, and it seems
devoid of major adverse effects.9,11,32 The dose of
riluzole used in this study (8 mg/kg) is the dose that
has been reported to be neuroprotective in several
studies.9,10 This study confirms that a single dose of
riluzole given before aortic clamping may result in
significant spinal cord protection, even in a setting of
severe ischemia. The addition of MgSO4 to riluzole
did not further improve neurologic outcome, com-
pared with riluzole given alone, suggesting that no
synergistic effect exists for those drugs when given in
combination. This association resulted in a better
neurological status than magnesium given alone (P
< .01), and the neurological outcome was better in
riluzole-treated rabbits than in magnesium-treated
rabbits (P < .01). These results suggest that riluzole
may be superior to MgSO4 (100 mg/kg) for the
prevention of spinal cord ischemic injury. The toler-
ance of the spinal cord to ischemia was demonstrat-
ed by means of the analysis of postoperative neuro-
logical status to be significantly increased by riluzole
and, to a lesser extent, by MgSO4. In addition, we
did not observe a secondary worsening of motor
deficits between 24 and 120 hours in riluzole-treat-
ed animals, as we did in magnesium-treated animals.
The worsening of neurological status and delayed
paraplegia have been reported in this model by other
investigators.33,34 Histopathologic and MAP-2
immunohistochemistry examinations confirmed that
riluzole prevented neuronal necrosis and ischemia-
induced cytoskeletal proteolysis. Riluzole was partic-
ularly effective in preventing motor neurons injury,
which is important because motor neurons are usu-
ally extremely sensitive to excitotoxicity and consti-
tute one of the main neuronal components that is
damaged after spinal cord ischemia.10, 33
The model used in this study is highly repro-
ducible. Severe spinal cord ischemia is induced,
which usually results in immediate and definitive
paraplegia in 100% of animals.33,34 The potential
limitations of this study include the use of halothane
and ketamine, which have been reported to be neu-
roprotective.35,36 In addition, we recorded an
approximately 1°C decrease in rectal temperature of
all animals between the onset and the end of the
procedure. All those factors may have influenced the
level of spinal cord ischemia.2,37 However, the use of
halothane and ketamine, and the mild decrease in
body temperature of animals cannot account for the
neuroprotective effects observed in riluzole-treated
and magnesium-treated animals, because control
animals that were operated on with the same condi-
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tions had a significantly worse neurological outcome
and definitive paraplegia. We did not measure blood
glucose concentration in any animal. It has been
widely demonstrated that blood glucose concentra-
tion affects ischemic spinal cord injury.38 However,
all rabbits in this study were fasted for 12 hours
before surgery, and none received glucose solution
preoperatively, making differences in blood glucose
concentrations among experimental groups highly
improbable.
CONCLUSION
The use of riluzole and MgSO4 resulted in no
major adverse effects and afforded significant neuro-
protection in this rabbit model of severe spinal cord
ischemia. Riluzole was clearly superior to MgSO4
(100 mg/kg) in preventing spinal cord ischemic
injury and related neurologic deficits. Considering
the beneficial use of both drugs in several models of
neuronal ischemia and the absence of reported
adverse effects in clinical studies involving these
drugs, our results support the evaluation of MgSO4
and riluzole for spinal cord protection during high-
risk thoracoabdominal aortic surgery.
We thank Hopital Foch (Suresnes) and Hopital
Pasteur (Nice) for the use of their experimental surgery
laboratories.
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